HanchorBio Inc. (TPEx: 7827.TWO), a pioneer of immunotherapy biologics, is announcing its official listing on the Taipei Exchange (TPEx) Emerging Stock Board under the ticker symbol 7827.TWO and the ...

Liminatus merged with blank check company Iris Acquisition Corp. in April to create a newly combined company called Liminatus Pharma Inc.

Explore the latest advancements in immunotherapies for T-cell lymphoma, addressing unique challenges and promising new ...

By Dennis Thompson HealthDay ReporterMONDAY, July 7, 2025 (HealthDay News) — Radiation therapy to treat cancer might be a ...

HanchorBio inks licensing pact with Shanghai Henlius Biotech to develop & commercialise HCB101 across Greater China: Taipei, Shanghai Saturday, July 5, 2025, 10:00 Hrs [IST] Hanch ...

HanchorBio signs licensing agreement with Shanghai Henlius Biotech to develop and commercialise rights to HCB101 across Greater China: Taipei, Shanghai Thursday, July 3, 2025, 11: ...

Pfizer's recent trial termination makes it yet another company facing challenges with CD47 studies in oncology.

Pfizer has terminated a Phase II study of its CD47 immune checkpoint inhibitor, maplirpacept, due to low recruitment. In an update on ClinicalTrials.gov, the company stated the study (NCT05626322 ...

Pfizer insists that the discontinuation of the Phase II study was due to recruitment difficulties and was not linked to maplirpacept’s safety or efficacy.

TAIPEI and SHANGHAI and SAN FRANCISCO, July 1, 2025 /PRNewswire/ -- HanchorBio Inc. (7827.TWO), a global clinical-stage biotechnology company developing innovative immunotherapies for oncology and ...

Fosun Pharma subsidiary Henlius Biotech is paying $10 million upfront for regional rights to HanchorBio’s phase 2-stage CD47 blocker.

Pending clinical outcomes, IBA101 may represent a more tolerable CD47 therapy option for combination immunotherapy regimens across multiple cancer types. About Liminatus Pharma ...